Drug Profile
Human amniotic epithelial cell therapy - Shanghai iCELL Biotechnology
Alternative Names: hAECs; hAESCs; Human amniotic epithelial stem cell therapy - Shanghai iCELL BiotechnologyLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Shanghai iCELL Biotechnology
- Developer Peking University People's Hospital; Shanghai iCELL Biotechnology
- Class Cell therapies; Stem cell therapies; Urologics
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Parkinson's disease
- No development reported Genitourinary disorders; Graft-versus-host disease
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In adolescents, In children, In the elderly, Prevention, In adults) in China (IV, Infusion)
- 16 Feb 2023 Phase-I clinical trials in Parkinson's disease (In adults, In the elderly) in China (Intraventricular)(NCT05691114)
- 19 Jan 2023 Shanghai iCELL Biotechnology plans a phase I trial for Parkinson's disease in China (Parenteral) in February 2023 (NCT05691114)